Squarepoint’s Phathom Pharmaceuticals PHAT Stock Holding History

Squarepoint’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$343K	Sell	31,595 -243,566	-89%	-$2.78M	﹤0.01%	3704
2026 Q1	$3.06M	Buy	+275,161	New	+$3.48M	﹤0.01%	1878
2023 Q4	–	Sell	-18,815	Closed	-$195K	–	4375
2023 Q3	$195K	Buy	+18,815	New	+$258K	﹤0.01%	3417
2023 Q1	–	Sell	-12,296	Closed	-$138K	–	3667
2022 Q4	$138K	Sell	12,296 -22,110	-64%	-$228K	﹤0.01%	2896
2022 Q3	$381K	Buy	34,406 +18,529	+117%	+$177K	﹤0.01%	2343
2022 Q2	$134K	Buy	+15,877	New	+$163K	﹤0.01%	2579
2021 Q2	–	Sell	-11,186	Closed	-$420K	–	3588
2021 Q1	$420K	Sell	11,186 -17,387	-61%	-$727K	﹤0.01%	2150
2020 Q4	$949K	Buy	+28,573	New	+$1.16M	0.01%	1371

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Squarepoint's PHAT Position: Q2 2026 in Review

Squarepoint reduced its Phathom Pharmaceuticals (PHAT) stake by 89% in Q2 2026, selling an estimated $2.78M and leaving 31,595 shares worth $343K. The position accounts for ﹤0.01% of the portfolio, ranked #3704.

Squarepoint first reported a position in PHAT in Q4 2020 and has held it in 8 quarters since. The position peaked at $3.06M in Q1 2026. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Squarepoint held 31,595 shares of Phathom Pharmaceuticals worth $343K as of Q2 2026.
Squarepoint sold 243,566 Phathom Pharmaceuticals shares in Q2 2026, an estimated $2.78M.
Phathom Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3704 holding.
Squarepoint first reported a position in Phathom Pharmaceuticals in Q4 2020 and has held it in 8 quarters since.
Squarepoint's Phathom Pharmaceuticals position peaked at $3.06M in Q1 2026.
162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.